CorMedix agrees to acquire substantially all Heron Therapeutics assets

• CorMedix will acquire substantially all Heron Therapeutics assets for $145 million cash and 14,583,333 common shares, valued together at approximately $222.6 million.
• Potential payments include up to $55 million tied to 2028 ZYNRELEF sales, with 5% royalties on qualifying 2027-2029 sales.
• The acquisition adds four commercial-stage products for postoperative pain and nausea prevention to CorMedix's institutional-care portfolio.
• CorMedix expects immediate earnings and free cash flow accretion, with $45-$60 million in annualized operating cost synergies by year-end 2027.
• Closing is expected in the first quarter of 2027; the seller will remain publicly traded but exit its current biotechnology operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9873025) on November 09, 2026, and is solely responsible for the information contained therein.